Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 6871-6880 Newer>

The Motley Fool November 11, 2010 Travis Hoium	This Chinese Stock Is in a Rut R&D isn't bringing a turnaround for American Oriental Bioengineering.
InternetNews November 11, 2010	Data Breaches Cost Hospitals $6B A Year: Study Ponemon Institute report finds that healthcare organizations suffer an average of 2.4 data breaches a year, costing in excess of $2 million per incident.
The Motley Fool November 11, 2010 Brian Orelli	Moderate Results, Moderate Rally for Dendreon Sometimes good enough really is good enough.
The Motley Fool November 9, 2010 Brian Orelli	Arena Pharmaceuticals Scores Some Points Overall, the recent Bloom-DM study leaves Arena in a slightly better position than it was in before the data was released, but this battle to get lorcaserin approved is far from over.
Chemistry World November 9, 2010 Andrew Turley	Stanford to challenge patent rights in Supreme Court The US Supreme Court has agreed to rule on the question of who owns intellectual property generated using billions of dollars of taxpayer money for medical research.
Chemistry World November 9, 2010 Andrew Turley	Company snapshot: Novo Nordisk As the results for the third quarter of this year roll in, one pharma major - Danish company Novo Nordisk - seems to have done better than most with its diabetes medicines.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool November 8, 2010 Esterhuizen & Sellitti	6 Executive Insiders Expecting a Health-Care Rally With the economy continuing to struggle, not to mention the passage of the health-care bill, the sector's expecting a lot of near-term volatility.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
<Older 6871-6880 Newer> Return to current articles.